Evidence map›Paper›PMID 35114692›Full record

ArticleThrombosis and haemostasis2022

CM-352 Efficacy in a Mouse Model of Anticoagulant-Associated Intracranial Hemorrhage.

Manuel Navarro-Oviedo, Juan Marta-Enguita, Carmen Roncal, Jose A Rodríguez, Beatriz Zandio, Ramón Lecumberri, Jose Hermida, Julen Oyarzabal, Antonio Pineda-Lucena, Jose A Páramo and 2 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Thrombosis and haemostasis, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 56% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Manuel Navarro-OviedoLaboratory of Atherothrombosis, CIMA Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra, IdisNA, Pamplona, Spain.ORCID 0000-0003-2095-5501
Juan Marta-EnguitaLaboratory of Atherothrombosis, CIMA Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra, IdisNA, Pamplona, Spain.ORCID 0000-0003-1807-4297
Carmen RoncalLaboratory of Atherothrombosis, CIMA Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra, IdisNA, Pamplona, Spain.ORCID 0000-0003-0616-9600
Jose A RodríguezLaboratory of Atherothrombosis, CIMA Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra, IdisNA, Pamplona, Spain.ORCID 0000-0002-2094-264X
Beatriz ZandioNeurology Department, Complejo Hospitalario de Navarra, IdisNA, Pamplona, Spain.
Ramón LecumberriCIBER Cardiovascular (CIBERCV), Instituto de Salud Carlos III, Spain.
Jose HermidaLaboratory of Atherothrombosis, CIMA Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra, IdisNA, Pamplona, Spain.ORCID 0000-0003-3154-4484
Julen OyarzabalSmall Molecules Platform, CIMA Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra, IdisNA, Pamplona, Spain.ORCID 0000-0003-1941-7255
Antonio Pineda-LucenaSmall Molecules Platform, CIMA Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra, IdisNA, Pamplona, Spain.
Jose A PáramoLaboratory of Atherothrombosis, CIMA Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra, IdisNA, Pamplona, Spain.ORCID 0000-0003-1497-6242
Roberto MuñozNeurology Department, Complejo Hospitalario de Navarra, IdisNA, Pamplona, Spain.ORCID 0000-0001-5518-7085
Josune OrbeLaboratory of Atherothrombosis, CIMA Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra, IdisNA, Pamplona, Spain.ORCID 0000-0001-6300-7670
Instituto de Salud Carlos III · ESNavarre Institute of Health Research · ESComplejo Hospitalario de Navarra · ES

Funding

FIS PI15/01807 Ministerio de Economía y Competitividad, Instituto de Salud Carlos IIIPI19/00065 Ministerio de Economía y Competitividad, Instituto de Salud Carlos III
6 · The paper itself

Abstract

backgroundIntracranial hemorrhage (ICH) is one of the major devastating complications of anticoagulation. Matrix metalloproteinase (MMP) inhibition has been proposed as a novel pharmacological approach for ICH treatment.

objectivesWe evaluated the effects of CM-352 (MMP-fibrinolysis inhibitor) in an experimental ICH model associated with oral anticoagulants as compared with clinically used prothrombin complex concentrate (PCC).

methodsICH was induced by collagenase injection into the striatum of wild type (C57BL/6J) anticoagulated mice (warfarin or rivaroxaban) and

resultsOnly PCC reduced hemorrhage volume and improved functional outcome in warfarin-ICH, but both PCC and CM-352 treatments diminished hemorrhage volume (46%,

conclusionCM-352 treatment, by diminishing MMPs and rivaroxaban-associated fibrinolytic effects, might be a novel antihemorrhagic strategy for rivaroxaban-associated ICH.

Indexed as

AnticoagulantsBenzamidesHydroxamic AcidsIntracranial HemorrhagesWarfarinAnimalsBlood Coagulation FactorsCerebral HemorrhageDisease Models, AnimalInterleukin-6Matrix Metalloproteinase 10MiceMice, Inbred C57BLPlasminogen Activator Inhibitor 1Rivaroxaban4-(4-((3-(hydroxycarbamoyl)-8-azaspiro(4.5)decan-3-yl)sulfonyl)phenoxy)-N-methylbenzamideAnticoagulantsBenzamidesBlood Coagulation FactorsHydroxamic AcidsInterleukin-6Matrix Metalloproteinase 10Plasminogen Activator Inhibitor 1RivaroxabanWarfarin

Identifiers

PMID35114692
PMCPMC9393087
OpenAlexW4210594726

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.